SenzaGen AB continues to gear up its operations

2014-11-12, Lund, Sweden

SenzaGen AB, a diagnostic spin-off company from Lund University, announces that Dr Carl-Henric Nilsson and Ann Gidner will join the board of directors.

SenzaGen AB, a diagnostic company working to replace animal testing, recently announced the recruitment of Dr. Anki Malmborg Hager as CEO. The company now continues to recruit top level associates and hereby announces that Dr Carl-Henric Nilsson and Ann Gidner will join the board.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, providing animal-free, in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

“We are entering into a very exciting commercial phase and are happy to be able to engage board members with international experience from our target markets,” says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

Carl-Henric Nilsson holds a PhD and M.Sc. in Industrial management, and is Associate Professor at Lund University, School of Economics and Management. He is CEO of Kunskapspartner AB, Chairman of Kunskapspartner Holding AB, Boardmember in FX International AB and Boffins Holding AB. Carl-Henric’s research is focused on Business development and Industrialization with numerous scientific publications. Carl-Henric is working with entrepreneurs on a global basis with a broad contact net, especially in China and the United States.

Ann Gidner holds a Master of Science in Chemical Engineering /Bioprocessing and a Bachelor in Business Administration. She has extensive international experience from the chemical industry with global leading positions in e.g. Cambrex and Lanxess Corporations. Furthermore, she has held managing positions in RFR Solutions AB, Semcon Caran AB, and Monocl AB. She is currently Director of Sales & Business Development Europe at Novozymes Biopharma, Copenhagen.

Other members of the board are chairman Carl Borrebaeck and deputy Malin Lindstedt.

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will offer the most accurate, animal-free in vitro testing option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

www.senzagen.com

For more information please contact:

Carl Borrebaeck, Chairman of the Board, SenzaGen AB

carl.borrebaeck@immun.lth.se

+46 708 218330

About Us

About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com About GARD GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

Subscribe